<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00050986</url>
  </required_header>
  <id_info>
    <org_study_id>ID02-126</org_study_id>
    <nct_id>NCT00050986</nct_id>
  </id_info>
  <brief_title>Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme</brief_title>
  <official_title>Phase I/II Evaluation Temozolomide and Farnesyl Transferase Inhibitor ZARNESTRA (R115777) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest safe dose of the new drug&#xD;
      ZARNESTRA (R115777) and temozolomide that can be given to patients with brain tumors&#xD;
      (glioblastoma multiforme, GBM). The second goal is to learn if these drugs given in&#xD;
      combination can shrink or slow the growth of brain tumors. The safety of this treatment will&#xD;
      also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Temozolomide works by killing cancer cells. R115777 is a new drug that may slow down the&#xD;
      growth of cancer cells. Used in combination, the two drugs may control the growth of brain&#xD;
      tumors.&#xD;
&#xD;
      Before treatment starts, patients will have a complete exam, including measurement of height&#xD;
      and weight. Blood tests (less than 2 tablespoons of blood) will be performed. A MRI scan will&#xD;
      be done. Women who are able have children must have a negative blood pregnancy test.&#xD;
&#xD;
      Temozolomide and R115777 will both be taken by mouth. Participants in this study will take&#xD;
      temozolomide once a day for 7 days every other week (Days 1-7 and 15-21). This will be&#xD;
      repeated every 28 days (1 course). Patients must not eat for 1 hour before and after taking&#xD;
      the drug; drinking water is allowed. All treatment may be given on an outpatient basis.&#xD;
&#xD;
      During the alternate weeks (Days 8-14 and 22-28), participants will take R115777 tablets by&#xD;
      mouth in the morning and evening with food. At the beginning of the study, groups of 3&#xD;
      participants each will take increasing doses of both R115777 and temozolomide until the&#xD;
      highest safe dose of each drug, when given in combination, is found. Participants entering&#xD;
      the study after the highest safe dose is found will receive that dosage.&#xD;
&#xD;
      If tumors do not grow and serious side effects do not occur, participants may keep on taking&#xD;
      temozolomide and R115777 for up to 2 year. If your physician thinks it is advisable,&#xD;
      treatment may continue with R115777 alone after that time. In this case, routine blood tests&#xD;
      for counts, liver and kidney function (less than 2 tablespoons) will be repeated every 4&#xD;
      weeks and MRI scans, physical, and neurological exams will be done every 8 weeks.&#xD;
      Participants may not receive any other treatment for cancer (including surgery) while taking&#xD;
      part in this study.&#xD;
&#xD;
      Participants will come to the clinic to have a complete physical and neurological exam and&#xD;
      blood tests (less than 2 tablespoons of blood) before each course. Blood tests will be&#xD;
      repeated once a week for the first 2 courses of treatment and then on Days 14 and 28 of each&#xD;
      later course. A MRI scan will be done before the odd-numbered (3, 5, 7, etc.) courses of&#xD;
      treatment or at any time clinically indicated.&#xD;
&#xD;
      At the end of the study, participants will have another complete physical exam. Blood tests&#xD;
      (less than 2 tablespoons of blood) will be performed. A MRI scan will be done.&#xD;
&#xD;
      This is an investigational study. Temozolomide is approved by the FDA for the treatment of&#xD;
      some brain tumors and is commercially available. R115777 is approved for research use only in&#xD;
      the treatment of brain tumors. The use of these two drugs together is experimental.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerating Dose (MTD for Phase I)</measure>
    <time_frame>End of first cycle (4 weeks) evaluation</time_frame>
    <description>Phase I Dose limiting toxicity evaluation at end of first cycle based on blood tests every two weeks and participants' subjective and objective symptoms.&#xD;
Start Dose Level 100 mg/m² Temozolomide once daily + 400 mg ZARNESTRA twice daily; Dose Level 1 100 mg/m² Temozolomide once daily + 500 mg ZARNESTRA twice daily; Dose Level 2 150 mg/m² Temozolomide once daily + 500 mg ZARNESTRA twice daily; Dose Level 3 150 mg/m² Temozolomide once daily + 600 mg ZARNESTRA twice daily; Dose Level 4 150 mg/m² Temozolomide once daily + 800 mg ZARNESTRA twice daily</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (Phase II)</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy measured by 6 month progression-free survival assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Temozolomide and R115777</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Starting Dose Level: 100 mg/m^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.</description>
    <arm_group_label>Temozolomide and R115777</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R115777</intervention_name>
    <description>Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.</description>
    <arm_group_label>Temozolomide and R115777</arm_group_label>
    <other_name>Zarnestra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically proven supratentorial glioblastoma multiforme (GBM).&#xD;
&#xD;
          2. Patients must have shown unequivocal evidence for tumor recurrence or progression by&#xD;
             MRI scan after radiation therapy. The scan done prior to study entry documenting&#xD;
             progression will be reviewed by the primary investigator to document tumor volume&#xD;
             changes to provide a gross assessment of growth rate.&#xD;
&#xD;
          3. Patients may have had: a) no prior chemotherapy, b) 1 prior adjuvant chemotherapy, c)&#xD;
             1 prior adjuvant chemotherapy followed by 1 regimen for recurrent disease, or d) 1 or&#xD;
             2 prior chemotherapy regimens for recurrent or progressive tumor.&#xD;
&#xD;
          4. All patients must sign an informed consent indicating that they are aware of the&#xD;
             investigational nature of this study in keeping with the policies of this hospital.&#xD;
&#xD;
          5. Patients must have shown unequivocal evidence for tumor progression by MRI or CT scan.&#xD;
             A scan should be performed within 14 days prior to registration and on a steroid dose&#xD;
             that has been stable for at least 5 days. If the steroid dose is increased between the&#xD;
             date of imaging and registration a new baseline MR/CT is required. The same type of&#xD;
             scan, i.e., MRI or CT must be used throughout the period of protocol treatment for&#xD;
             tumor measurement.&#xD;
&#xD;
          6. Pts with recent resection of recurrent or progressive tumor will be eligible if all of&#xD;
             the following conditions apply: Pt has recovered from the effects of surgery; Residual&#xD;
             disease after resection of recurrent tumor is not mandated for eligibility. To assess&#xD;
             the extent of residual disease post-operatively, a CT/MRI should be done no later than&#xD;
             96 hours post-operatively or at least 4 weeks post-operatively, and within 14 days&#xD;
             before registration. If steroid dose increased between the day of imaging and&#xD;
             registration, a new baseline scan is required after stable steroids for 5 days.&#xD;
&#xD;
          7. Patients must have a Karnofsky performance status of &gt;/= 60&#xD;
&#xD;
          8. Patients must have recovered from the toxic effects of prior therapy: 4 weeks from&#xD;
             prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from&#xD;
             nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic&#xD;
             agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc.&#xD;
             (radiosensitizer does not count). Any questions related to the definition of&#xD;
             non-cytotoxic agents should be directed to the Study Chair.&#xD;
&#xD;
          9. Patients must have adequate bone marrow function (ANC&gt;/= 1,500/mm(3) and platelet&#xD;
             count of &gt;/= 100,000/mm(3)), adequate liver function (SGPT and SGOT &lt;/= 2.5 times&#xD;
             normal, bilirubin &lt;/= 2 mg%), and adequate renal function (BUN and creatinine &lt;1.5&#xD;
             times institutional normal) prior to starting therapy.&#xD;
&#xD;
         10. ZARNESTRA may interfere with coumadin dosing and patients who are taking this&#xD;
             combination will require more frequent monitoring of their PT, PTT and INR.&#xD;
&#xD;
         11. Patient has no risk factors for HIV or is serologically negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients must not be taking primidone, carbamazepine, phenobarbital or phenytoin&#xD;
             anticonvulsants. Patients changing from these anticonvulsants to others that are&#xD;
             allowed must be off the drugs listed above for at least 1 week.&#xD;
&#xD;
          2. Patients must not be taking cimetidine, erythromycin azole antifungals, paclitaxel,&#xD;
             tacrolimus or cyclosporine.&#xD;
&#xD;
          3. Patients must not have uncontrolled high blood pressure, unstable angina, symptomatic&#xD;
             congestive heart failure, myocardial infarction within the previous six months, or&#xD;
             serious uncontrolled cardiac arrhythmia.&#xD;
&#xD;
          4. Because of the concerns of potentially harmful interactions of ZARNESTRA and other&#xD;
             medications taken by patients who are HIV positive or have AIDS related diseases,&#xD;
             patients who are HIV positive will not be eligible for entry into this study. Only&#xD;
             patients with suspected HIV will be tested and if positive, will be ineligible.&#xD;
&#xD;
          5. Patients with a history of any other cancer (except non-melanoma skin cancer or&#xD;
             carcinoma in-situ of the cervix) are ineligible unless in complete remission and off&#xD;
             of all therapy for that disease for a minimum of 3 years.&#xD;
&#xD;
          6. Patients must not have: a) active infection b) disease that will obscure toxicity or&#xD;
             dangerously alter drug metabolism c) serious intercurrent medical illness. d) prior&#xD;
             recurrence with either Temozolomide or a farnesyl transferase inhibitor.&#xD;
&#xD;
          7. Patients must not be pregnant and must practice adequate contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R. Gilbert</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDAnderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 31, 2002</study_first_submitted>
  <study_first_submitted_qc>January 2, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2003</study_first_posted>
  <results_first_submitted>September 25, 2009</results_first_submitted>
  <results_first_submitted_qc>August 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2010</results_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Neoplasms</keyword>
  <keyword>CNS Diseases</keyword>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Temodar</keyword>
  <keyword>R115777</keyword>
  <keyword>Zarnestra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total of 55 participants recruited in between 12/30/2002 and 11/30/2005, all at M. D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>5 patients were not evaluated for response because of the following: 1 early, non-treatment related death; 3 withdrew consent; 1 discontinued for intercurrent illness (pneumonia).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Temozolomide and R115777</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53">Two participants had withdrawn consents before the study treatment was initiated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide and R115777</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="21" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Tolerating Dose (MTD for Phase I)</title>
        <description>Phase I Dose limiting toxicity evaluation at end of first cycle based on blood tests every two weeks and participants' subjective and objective symptoms.&#xD;
Start Dose Level 100 mg/m² Temozolomide once daily + 400 mg ZARNESTRA twice daily; Dose Level 1 100 mg/m² Temozolomide once daily + 500 mg ZARNESTRA twice daily; Dose Level 2 150 mg/m² Temozolomide once daily + 500 mg ZARNESTRA twice daily; Dose Level 3 150 mg/m² Temozolomide once daily + 600 mg ZARNESTRA twice daily; Dose Level 4 150 mg/m² Temozolomide once daily + 800 mg ZARNESTRA twice daily</description>
        <time_frame>End of first cycle (4 weeks) evaluation</time_frame>
        <population>As treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide and R115777</title>
          </group>
        </group_list>
        <measure>
          <title>Maximal Tolerating Dose (MTD for Phase I)</title>
          <description>Phase I Dose limiting toxicity evaluation at end of first cycle based on blood tests every two weeks and participants' subjective and objective symptoms.&#xD;
Start Dose Level 100 mg/m² Temozolomide once daily + 400 mg ZARNESTRA twice daily; Dose Level 1 100 mg/m² Temozolomide once daily + 500 mg ZARNESTRA twice daily; Dose Level 2 150 mg/m² Temozolomide once daily + 500 mg ZARNESTRA twice daily; Dose Level 3 150 mg/m² Temozolomide once daily + 600 mg ZARNESTRA twice daily; Dose Level 4 150 mg/m² Temozolomide once daily + 800 mg ZARNESTRA twice daily</description>
          <population>As treated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose Level 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Level 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Level 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Level 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (Phase II)</title>
        <description>Efficacy measured by 6 month progression-free survival assessment.</description>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 11 months</time_frame>
      <desc>Including all serious adverse events regardless of attribution. Including all grade 3 or higher adverse events regardless of attribution.</desc>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide and R115777</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>CNS Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>hypophasphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Amyliase, Lipase, Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Due to tumor progression. Not related to the study drugs</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Depressed level of consiousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pyramidal Tract Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <description>Pulmonary Embolism and deep vein thrombosis</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="76" subjects_affected="21" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphocytopenia</sub_title>
                <counts group_id="E1" events="210" subjects_affected="40" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="16" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mental Status</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Motor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonits</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>decubitus Ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>W.K. Yung,MD/Clinical Professor, Neuro-Oncology</name_or_title>
      <organization>University of Texas, M. D. Anderson Cancer Center</organization>
      <phone>(713) 794-1285</phone>
      <email>wyung@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

